Progesterone modulates the DSCAM-AS1/miR-130a/ESR1 axis to suppress cell invasion and migration in breast cancer

• Published in: Breast cancer research : BCR Vol. 24; no. 1; pp. 97 - 13
• Main Authors: Yadav, Neelima, Sunder, Roma, Desai, Sanket, Dharavath, Bhasker, Chandrani, Pratik, Godbole, Mukul, Dutt, Amit
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 28-12-2022; BioMed Central; BMC
• Subjects: Analysis; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Cell Line, Tumor; Cell Movement - genetics; Cell Proliferation - genetics; Down syndrome; DSCAM-AS1; Estrogen; Estrogen receptor; Female; Gene Expression Regulation, Neoplastic; Humans; Hydroxyprogesterone; Medical research; Medicine, Experimental; MicroRNAs - genetics; miR-130a; Progesterone; Progesterone - pharmacology; Progesterone receptor; RNA; RNA, Long Noncoding - genetics; Estrogen receptor; Breast cancer; Progesterone; DSCAM-AS1; Progesterone receptor; miR-130a
• ISSN: 1465-542X; 1465-5411; 1465-542X
• DOI: 10.1186/s13058-022-01597-x

A preoperative-progesterone intervention increases disease-free survival in patients with breast cancer, with an unknown underlying mechanism. We elucidated the role of non-coding RNAs in response to progesterone in human breast cancer.
Whole transcriptome sequencing dataset of 30 breast primary tumors (10 tumors exposed to hydroxyprogesterone and 20 tumors as control) were re-analyzed to identify differentially expressed non-coding RNAs followed by real-time PCR analyses to validate the expression of candidates. Functional analyses were performed by genetic knockdown, biochemical, and cell-based assays.
We identified a significant downregulation in the expression of a long non-coding RNA, Down syndrome cell adhesion molecule antisense DSCAM-AS1, in response to progesterone treatment in breast cancer. The progesterone-induced expression of DSCAM-AS1 could be effectively blocked by the knockdown of progesterone receptor (PR) or treatment of cells with mifepristone (PR-antagonist). We further show that knockdown of DSCAM-AS1 mimics the effect of progesterone in impeding cell migration and invasion in PR-positive breast cancer cells, while its overexpression shows an opposite effect. Additionally, DSCAM-AS1 sponges the activity of miR-130a that regulates the expression of ESR1 by binding to its 3'-UTR to mediate the effect of progesterone in breast cancer cells. Consistent with our findings, TCGA analysis suggests that high levels of miR-130a correlate with a tendency toward better overall survival in patients with breast cancer.
This study presents a mechanism involving the DSCAM-AS1/miR-130a/ESR1 genomic axis through which progesterone impedes breast cancer cell invasion and migration. The findings highlight the utility of progesterone treatment in impeding metastasis and improving survival outcomes in patients with breast cancer.